- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | NeOnc Technologies secures $5M private placement via Series A preferred stock | 2 | Seeking Alpha | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Fr | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | 24/7 Market News and NeOnc Technology: The Next Great AI Revolution May Be Drug Delivery | 2 | GlobeNewswire (USA) | ||
| 19.05. | 24/7 Market News and NeOnc Technology: NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones | 1 | GlobeNewswire (USA) | ||
| 18.05. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | NeOnc Technologies Holdings GAAP EPS of -$0.38 | 2 | Seeking Alpha | ||
| 18.05. | NeOnc Technologies Holdings, Inc.: NeOnc Provides Business Update and Reports Q1 2026 Financial Results | 851 | GlobeNewswire (Europe) | CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs... ► Artikel lesen | |
| 07.05. | 24/7 Market News and NeOnc Technology: Biotech's Next Wave May Already be in Motion | 1 | GlobeNewswire (USA) | ||
| 24.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.04. | BTIG stuft NeOnc Technologies mit "Kaufen" ein - Hoffnungsträger bei ZNS-Tumoren | 12 | Investing.com Deutsch | ||
| 24.04. | BTIG initiates NeOnc Technologies stock with buy on CNS tumor drugs | 1 | Investing.com | ||
| 18.04. | New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings, Neonc Technologies Holdings, Medicus Pharma, YY Group Holding, and Vivos Therapeutics | 828 | ACCESS Newswire | The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution... ► Artikel lesen | |
| 14.04. | NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 10.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | NeOnc Technologies Holdings GAAP EPS of -$3.20 | 2 | Seeking Alpha | ||
| 01.04. | NeOnc Technologies Holdings, Inc.: NeOnc Provides Business Update and Reports Q4 2025 Financial Results | 153 | GlobeNewswire (Europe) | CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 31.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 23.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.03. | NeOnc Technologies appoints David Choi as chief accounting officer | 1 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,768 | +2,41 % | Evotec nach dem Absturz: Droht noch mehr Druck auf die Aktie? | Die Aktie von Evotec bleibt nach den jüngsten Geschäftszahlen unter Druck. Zwar wächst das operative Geschäft weiter, doch sinkende Gewinne und hohe Investitionen sorgen für Verunsicherung bei Anlegern.... ► Artikel lesen | |
| MODERNA | 43,100 | -0,10 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| VALNEVA | 2,271 | -0,70 % | Was Insider bei Valneva zum Wochenstart bereits wissen: Die Entwicklung die jetzt niemand auf dem Schirm hat - Was sich am Wochenende verändert hat! | ||
| PALATIN TECHNOLOGIES | 13,920 | +2,28 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,140 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,440 | -0,19 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,550 | -3,53 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| XOMA ROYALTY | 35,800 | -0,56 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 12.06.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.06.2026.ISIN NameAU0000154148 HARTSHEAD... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,260 | +1,35 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer | OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical... ► Artikel lesen | |
| NOVOCURE | 14,335 | -6,70 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,108 | -0,63 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| CYTOKINETICS | 60,40 | -0,40 % | Cytokinetics, Incorporated: Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program | ||
| TRAWS PHARMA | 1,280 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Provides Regulatory Update on Influenza Program | NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats... ► Artikel lesen |
Das Unternehmen NEONC TECHNOLOGIES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,68 % bei einem Aktienkurs von 4,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.